<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085523</url>
  </required_header>
  <id_info>
    <org_study_id>TCC-201</org_study_id>
    <nct_id>NCT04085523</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia</brief_title>
  <official_title>ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 12 Months in Prepubertal Children With Achondroplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascendis Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascendis Pharma A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation
      trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10
      years old, inclusive, with Achondroplasia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are 5 cohorts enrolling approximately 60 subjects who will be randomized to receive either TransCon CNP or Placebo in a 3:1 ratio</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Safety and tolerability of once weekly TransCon CNP treatment or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized height velocity (centimeters/year) at 52 weeks</measure>
    <time_frame>52 weeks</time_frame>
    <description>Annualized height velocity measured in centimeters over 52 weeks for TransCon CNP or placebo</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Achondroplasia</condition>
  <arm_group>
    <arm_group_label>TransCon CNP 6 mcg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TransCon CNP 6 mcg CNP/kg or placebo mimicking TransCon CNP 6 mcg delivered once weekly by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TransCon CNP 20 mcg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TransCon CNP 20 mcg CNP/kg or placebo mimicking TransCon CNP 20 mcg delivered once weekly by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TransCon CNP 50 mcg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TransCon CNP 50 mcg CNP/kg or placebo mimicking TransCon CNP 50 mcg delivered once weekly by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TransCon CNP 100 mcg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TransCon CNP 100 mcg CNP/kg or placebo mimicking TransCon CNP 100 mcg delivered once weekly by subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TransCon CNP &gt;100 mcg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TransCon CNP &gt;100 mcg CNP/kg delivered once weekly by subcutaneous injection (to be determined after completion of 100 mcg cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TransCon CNP</intervention_name>
    <description>TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.</description>
    <arm_group_label>TransCon CNP 100 mcg</arm_group_label>
    <arm_group_label>TransCon CNP 20 mcg</arm_group_label>
    <arm_group_label>TransCon CNP 50 mcg</arm_group_label>
    <arm_group_label>TransCon CNP 6 mcg</arm_group_label>
    <arm_group_label>TransCon CNP &gt;100 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for TransCon CNP</intervention_name>
    <description>The placebo for TransCon CNP contains the same excipients as TransCon CNP drug product but does not contain TransCon CNP. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.</description>
    <arm_group_label>TransCon CNP 100 mcg</arm_group_label>
    <arm_group_label>TransCon CNP 20 mcg</arm_group_label>
    <arm_group_label>TransCon CNP 50 mcg</arm_group_label>
    <arm_group_label>TransCon CNP 6 mcg</arm_group_label>
    <arm_group_label>TransCon CNP &gt;100 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis of ACH with genetic confirmation

          2. Age between 2 to 10 years old (inclusive) at Screening Visit

          3. Prepubertal (Stage 1 breasts for girls or testicular volume &lt; 4ml for boys) at
             Screening Visit

          4. Able to stand without assistance

          5. Caregiver willing and able to administer subcutaneous injections of study drug

        Exclusion Criteria:

          1. Clinically significant findings at Screening that:

               -  are expected to require surgical intervention during participation in the trial
                  or

               -  are musculoskeletal in nature, such as Salter-Harris fractures and severe hip
                  pain or

               -  otherwise are considered by investigator or Medical Monitor/Medical Expert to
                  make a participant unfit to receive study drug or undergo trial related
                  procedures

          2. Have received treatment (&gt;3 months) of human growth hormone (hGH) or other medications
             known to affect stature or body proportionality at any time

          3. Have received any dose of medications intended to affect stature or body
             proportionality within the previous 6 months of Screening Visit

          4. Have received any study drug or device intended to affect stature or body
             proportionality at any time

          5. History or presence of injury or disease of the growth plate(s), other than
             Achondroplasia, that affects growth potential of long bones
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Charlton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ascendis Pharma A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Affairs Director</last_name>
    <phone>+1 855-795-2467</phone>
    <phone_ext>4420</phone_ext>
    <email>accomplishtrial@ascendispharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascendis Pharma Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Achondroplasia</keyword>
  <keyword>Dwarfism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

